BMS's Nivolumab Kidney Cancer Data Available At ASCO At 3 PM CST Tomorrow

This will be one of the very first early signs of how far ahead (and a harbinger of how efficacious, actually) nivolumab is going to turn out to be. Overall, by Monday night, we will know much much more.

And so, per Adam Feuerstein:

. . . .The other significant Saturday oral presentations features PD-1 immunotherapy data in kidney cancer from Bristol-Myers Squibb (BMY). Those start at 4 pm ET. . . .

Do stay tuned on this high school graduations weekend for many around the nation. Way to go, all you young science grads!